Sermorelin EMA vs FDA: What the Regulatory Difference Means for Women

What the FDA Actually Approved for Sermorelin (and What It Did Not)

The FDA approved sermorelin acetate in 1997 under the brand name Geref for a single indication: long-term treatment of idiopathic growth hormone deficiency in children who had open epiphyses. That approval was anchored in pediatric data, most notably the Walker et al. Trial published in Pediatrics in 1990, which demonstrated that sermorelin stimulated pulsatile growth hormone (GH) secretion and improved linear growth velocity in children with GH deficiency.

The adult indication was never approved.

In 2008, Serono voluntarily withdrew Geref from the US market. The FDA's withdrawal classification matters here: it was not a safety-driven removal. The agency's records confirm the withdrawal was for commercial reasons, which means the original safety and efficacy data remain intact in the regulatory docket. That distinction is clinically relevant because it means the compound itself is not considered unsafe by the FDA; the approved product simply stopped being manufactured.

Why the Withdrawal Classification Matters to You as a Patient

When a drug is withdrawn for safety reasons, compounding pharmacies face strict restrictions. A commercially withdrawn drug removed for non-safety reasons occupies different legal territory under 21 U.S.C. § 353a, allowing 503A pharmacies to compound it for individual patients with a valid prescription. This is the legal foundation on which virtually all adult sermorelin prescribing in the United States currently rests.

The practical consequence: your sermorelin comes from a compounding pharmacy, not a licensed manufacturer, which means no FDA lot-release testing, no standardized excipients, and no formal post-market surveillance program attached to the product you actually receive.

The Original Geref Label: Key Language

The original prescribing information for Geref specified subcutaneous injection at bedtime to align with the physiologic nocturnal GH pulse. The label listed contraindications including active malignancy, untreated hypothyroidism, and known hypersensitivity to sermorelin or its components. It also explicitly noted that GH secretory capacity must be confirmed before treatment, meaning a stimulation test or documented deficiency, not a low-normal IGF-1 alone.

None of this label language was written with adult women in mind. The pediatric framing is embedded throughout.

The EMA's Position: No Approval, No EPAR

The European Medicines Agency has never granted a marketing authorization for sermorelin in any indication, for any age group. There is no European Public Assessment Report (EPAR) for sermorelin. This is not a regulatory gap waiting to be filled; it reflects a deliberate absence of marketing applications from any sponsor.

European patients who use sermorelin do so through individual member-state named-patient programs or unlicensed medicine pathways, which vary considerably by country. The UK's MHRA similarly carries no product license for sermorelin. This is a meaningful contrast to the FDA situation, where at least a historical approval exists to anchor the compound's known safety profile.

What the EMA Has Approved Instead

For adult growth hormone deficiency, the EMA has approved recombinant human GH (somatropin) products, including Genotropin, Norditropin, and Omnitrope, under full marketing authorizations with strong adult and female-specific data. The EMA's approach to adult GHD centers on direct GH replacement rather than secretagogue stimulation, which is a pharmacologically different strategy.

This matters for women because the EMA-approved somatropin labels include specific dosing guidance for women, noting that women require higher GH doses than men due to differences in GH sensitivity driven by estrogen status. Oral contraceptive use and post-menopausal estrogen therapy both reduce hepatic IGF-1 generation, meaning a woman on estrogen needs more GH replacement to achieve the same IGF-1 target. That sex-specific pharmacokinetic data does not exist in any sermorelin label because sermorelin was never studied in adult women in a regulatory context.

Sex-Specific Physiology: How Being a Woman Changes the Sermorelin Picture

This is where the regulatory gap becomes a clinical gap. No FDA-approved trial and no EMA-approved program has generated female-specific sermorelin pharmacokinetic or pharmacodynamic data in adults. What exists comes from small, often male-dominant research cohorts and from the inference of GH physiology literature more broadly.

Estrogen, GH Pulsatility, and the Menstrual Cycle

GH secretion is not static across your menstrual cycle. Estradiol amplifies GH pulse amplitude, particularly in the follicular phase. This means that during the high-estrogen follicular phase, sermorelin may produce a larger GH response than during the low-estrogen luteal phase or during the estrogen-deficient years of post-menopause.

Practically, this could mean that a fixed nightly dose of sermorelin produces variable IGF-1 responses depending on where you are in your cycle. No published dose-adjustment protocol exists for cycle-phase-dependent sermorelin dosing. Clinicians prescribing sermorelin to pre-menopausal women are extrapolating from GH physiology literature, not from sermorelin-specific trial data. That extrapolation may be reasonable, but patients deserve to know it is extrapolation.

Perimenopause and Post-Menopause

GH secretion declines with age in both sexes, but the trajectory in women is steepened by the loss of estradiol at menopause. IGF-1 levels fall approximately 14% per decade across adulthood, with a more pronounced drop in the post-menopausal years. Women in perimenopause often present with symptoms that overlap with GH insufficiency: disrupted sleep, central adiposity, reduced lean mass, and cognitive fog. Sermorelin is frequently marketed to this population precisely because of that symptom overlap.

The absence of a formal EMA or FDA approval for this use means there is no consensus-defined IGF-1 target for post-menopausal women on sermorelin, no agreed monitoring interval, and no post-market safety database tracking outcomes in this group.

PCOS and Insulin Sensitivity

Women with polycystic ovary syndrome (PCOS) have altered GH-IGF-1 axis signaling. Some research suggests that GH secretion may be increased in lean PCOS but blunted in obese PCOS, with IGF-1 levels varying accordingly. Sermorelin's effect on insulin sensitivity in women with PCOS has not been studied in any controlled trial. Because GH itself is insulin-antagonizing at the receptor level, there is a plausible concern that sermorelin could worsen insulin resistance in women with PCOS who already carry metabolic risk. This concern is theoretical but not trivial.

The WomanRx Regulatory-to-Clinical Translation Framework for Sermorelin:

| Regulatory gap | Clinical consequence for women | What to ask your prescriber | |---|---|---| | No adult FDA label | No approved adult dose, no label-defined monitoring | What IGF-1 target are you using and why? | | No female PK data | Unknown cycle-phase dose variability | Should my dose vary across my cycle? | | No PCOS-specific data | Insulin sensitivity risk unquantified | Do I need a fasting insulin panel before starting? | | No EMA approval | No European post-market safety data | What adverse event reporting system tracks my outcomes? | | Compounding source | Variable potency, sterility risk | Is this pharmacy 503A accredited and USP 797 compliant? |

How Compounding Changes the Safety Equation

Because no manufacturer holds an active NDA for sermorelin, every vial of sermorelin dispensed to an adult woman in the United States today is compounded. Section 503A of the Food, Drug, and Cosmetic Act permits licensed pharmacies to compound drugs for individual patients based on a practitioner's prescription, provided the drug is not on the FDA's list of drugs that may not be compounded due to safety concerns.

Sermorelin is not on that prohibited list. But compounded drugs are not FDA-approved, which means:

• Potency may vary between batches and between pharmacies.
• Sterility testing standards are set by USP <797>, not by FDA lot-release criteria.
• No mandatory adverse event reporting applies to compounded products in the same way it applies to approved drugs.
• Your insurer almost certainly will not cover it.

A 2022 analysis by the FDA's Center for Drug Evaluation and Research found that compounded injectable drugs accounted for a disproportionate share of adverse event reports relative to their market share. Sermorelin-specific compounding complaints have not generated a public warning letter to date, but the general compounding risk framework applies.

What to Look for in a Compounding Pharmacy

Ask specifically whether your pharmacy holds 503B outsourcing facility registration or is operating as a 503A pharmacy. A 503B outsourcing facility is subject to current Good Manufacturing Practice standards and FDA inspection, which is meaningfully higher oversight. Most compounded sermorelin currently comes from 503A pharmacies, which are state-regulated and not routinely FDA-inspected.

Verify USP <797> compliance for sterile preparations. Request a Certificate of Analysis for the specific batch you receive. These are reasonable, standard questions; a reputable pharmacy will answer them without hesitation.

Pregnancy, Lactation, and Contraception: Required Reading

Sermorelin is not approved for use in pregnancy. Do not use it if you are pregnant, planning to become pregnant in the near term, or if you are not using reliable contraception and pregnancy is possible.

Pregnancy Data

There is no adequate or well-controlled human trial data on sermorelin use in pregnancy. Animal reproduction studies are limited. The original Geref prescribing information did not establish a formal pregnancy category under the old FDA A/B/C/D/X classification system, but the compound was approved for pediatric use only, making pregnancy data in the label essentially absent.

The theoretical concern with sermorelin in pregnancy centers on the GH axis. GH and IGF-1 signaling are central to fetal growth, and exogenous manipulation of this axis during organogenesis or fetal development carries unknown risk. Until human data exists, the precautionary position is to discontinue sermorelin before attempting conception.

Lactation

It is unknown whether sermorelin or its metabolites transfer into breast milk. Given the peptide's molecular weight and the fact that it is administered subcutaneously, some systemic exposure exists, and transfer into milk cannot be ruled out. The effect on a nursing infant is unknown.

The Drugs and Lactation Database (LactMed) maintained by the NIH does not contain a sermorelin entry, reflecting the absence of any published human lactation data. The prudent clinical position is to avoid sermorelin during breastfeeding.

Contraception Requirements

Women of reproductive age prescribed sermorelin should use reliable contraception. This is not a formal label requirement (because no adult label exists) but reflects the absence of pregnancy safety data and the standard of care for any peptide with uncharacterized teratogenic potential. Discuss your contraception method with your prescriber before starting.

Who This May Be Right For, and Who Should Pause

Potentially Appropriate Candidates

• Post-menopausal women with documented GH insufficiency confirmed by stimulation testing, who have been evaluated by a board-certified endocrinologist and who have normal thyroid function.
• Perimenopausal women with confirmed low IGF-1 and sleep-related GH disruption, who have discussed the off-label and compounding context explicitly with their clinician.
• Women with age-related sarcopenia and metabolic syndrome who have not responded to optimized nutrition and exercise and who have endocrinologic confirmation of GH axis dysfunction.

Who Should Not Use Sermorelin

• Pregnant women, women actively trying to conceive, and breastfeeding women.
• Women with active malignancy or a personal history of hormone-sensitive cancers, given the theoretical IGF-1-mediated growth promotion concern.
• Women with untreated hypothyroidism. Thyroid hormone is required for GH action at the receptor level; starting sermorelin without optimizing thyroid status is physiologically counterproductive and was explicitly listed as a contraindication in the original Geref label.
• Women with PCOS who have uncontrolled insulin resistance, until a metabolic workup has been completed and the risk-benefit discussion has occurred with a clinician familiar with both GH biology and PCOS.

Monitoring: What the Data Suggests Without a Label to Follow

Because no approved adult label exists, monitoring protocols are drawn from the adult GHD literature, primarily the Growth Hormone Research Society consensus guidelines and the Endocrine Society's clinical practice guideline on adult GHD published in the Journal of Clinical Endocrinology and Metabolism.

Those guidelines recommend monitoring IGF-1 at baseline and at 4 to 6 week intervals during dose titration, with a target of the age- and sex-normalized reference range, typically the 50th to 75th percentile for your age group. Glucose and HbA1c should be checked at baseline and at 3 to 6 month intervals given GH's insulin-antagonizing effect. Women on estrogen therapy need IGF-1 interpreted in the context of estrogen's suppressive effect on hepatic IGF-1 generation.

Fasting glucose, lipid panel, and thyroid function at baseline are reasonable minimum requirements before starting. Some clinicians also check cortisol and adrenal function, given that GH deficiency often co-exists with other pituitary deficiencies.

The Regulatory Timeline: A Concise Chronology

Understanding how sermorelin got to its current status helps you evaluate where the evidence base actually begins and ends.

• 1990: Walker et al. Publish the key pediatric trial in Pediatrics, demonstrating sermorelin's ability to stimulate GH secretion and improve linear growth in GH-deficient children. This becomes a foundational citation in the Geref NDA. The trial enrolled 60 children across multiple centers.
• 1997: FDA approves Geref for pediatric idiopathic GH deficiency. Adult use is not part of the approved indication.
• 2002 to 2007: Research interest grows in GH secretagogues for aging adults. Small trials begin examining sermorelin and related peptides in older men and women, but none reach the scale required for a supplemental NDA.
• 2008: Serono voluntarily withdraws Geref from the US market. No safety signal triggers the withdrawal.
• 2008 to present: Compounding pharmacies fill the supply gap. Adult off-label prescribing grows, particularly in concierge medicine, anti-aging, and telehealth practices.
• 2023 to 2025: The FDA's increased scrutiny of compounded GLP-1 peptides generates broader regulatory attention to compounded peptide injectables. Sermorelin has not been specifically targeted, but the regulatory environment for compounded peptides overall is tightening.

What the Evidence Gap Means in Practice

Women have been historically under-represented in peptide hormone trials. The adult sermorelin literature that does exist skews heavily male. A 2001 multi-site study examining sermorelin's effect on body composition and sleep quality enrolled predominantly men over 60. The few women included were post-menopausal, and results were not disaggregated by sex in the primary analysis.

This is not unique to sermorelin; it reflects a systemic gap in endocrine research. But it means that when a clinician quotes you an expected benefit from sermorelin, they are either drawing on GH physiology research conducted in men or extrapolating from somatropin trial data in women, neither of which is direct evidence for sermorelin's effects in adult women at any life stage.

That evidence gap is not a reason to automatically reject sermorelin if you and your clinician have concluded that documented GH insufficiency warrants treatment and that somatropin is not an acceptable alternative. It is a reason to demand documented IGF-1 monitoring, conservative dosing, and a clear stopping rule if your IGF-1 moves above the normal range for your age.